Crizotinib shows promise in ROS1-rearranged advanced NSCLC
Crizotinib induced a high response rate in patients with advanced non–small cell lung cancer who harbored
Alice T. Shaw, MD, PhD, a thoracic oncologist at Massachusetts General Hospital Cancer Center, and colleagues sought to evaluate the efficacy of crizotinib (Xalkori, Pfizer) — a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (
Alice T. Shaw
Three patients demonstrated a complete response, and 33 patients demonstrated a partial response. Using these data, researchers calculated an objective response rate of 72% (95% CI, 58-84).
The median duration of response was 17.6 months (95% CI, 14.5-not reached), and median PFS was 19.2 months (95% CI, 14.4-not reached). Twenty-five patients were still in follow-up for progression at the time of the analysis.
Median follow-up for OS was 16.4 months. Researchers reported a 12-month OS rate of 85% (95% CI, 72-93). Median OS had not been reached.
Researchers also evaluated
The most common fusion partner was the gene encoding CD74 (44%). Researchers also detected four other previously known
However, there was no association between the type of
Most treatment-related adverse events were grade 1 or grade 2 (94%). The most common adverse events were visual impairment (82%), diarrhea (44%), nausea (40%), peripheral edema (40%), constipation (34%) and vomiting (34%).
Disclosure: The study was funded in part by Pfizer and grants from the NCI, Uniting against Lung Cancer and Be a Piece of the Solution. See the study for a full list of the researchers’ relevant financial disclosures.